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Abstract
Porphyromonas gingivalis, a major subgingival plaque bacterium in periodontitis, has recently attracted much attention as a
possible microbial driver in Alzheimer’s disease. In the present paper, another common neuroinflammatory disease, Parkinson’s
disease (PD), is discussed. A recent study found major virulence factors of P. gingivalis such as gingipain R1 (RgpA) and
lipopolysaccharide in the blood circulation of a PD population. The current review reveals how features such as systemic
inflammation, hypercoagulation, presence of amyloid fibrin(ogen) in plasma, and marked ultrastructural changes in platelets,
probably induced by P. gingivalis, may affect the development of PD. Several other clinical studies have also demonstrated an
association between periodontitis and PD. Even if the risk of periodontal diseases causing neurological disorders needs to be
better substantiated, that should not keep us from trying to prevent them by performing careful daily dental hygiene.
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Introduction
Periodontitis is a collection of diseases where microorganisms
cause destruction of the tooth-supporting structures through
poorly controlled inflammatory responses. A world workshop
held in 2017 distinguished periodontitis in three clinical
forms: necrotizing periodontitis, periodontitis as a manifesta-
tion of systemic disease, and the forms of the disease previ-
ously recognized as chronic or aggressive, now grouped under
a single category, periodontitis [1].
The oral cavity contains up to 1000 different bacteria lo-
calized in different niches, each with a characteristic microbi-
ota [2]. A homeostatic balance exists most of the time between
host and oral microbes, but this can be tipped towards disease.
Traditional culture-based methods emphasized the anaerobic
Gram-negative rods Porphyromonas gingivalis, Tannerella
forsythia, and Treponema denticola (the red complex) as the
major pathogens of periodontitis [3]. Culture-independent
methods have extended this list to comprise both Gram-
positive and Gram-negative bacteria (reviewed by Lamont
et al. [4]). Among all these species P. gingivalis has emerged
as a keystone bacterium in periodontitis [5, 6].
In periodontitis, polymicrobial communities initiate a dys-
regulated host response through polymicrobial synergy and
dysbiosis [7]. As a keystone pathogen, P. gingivalis increases
the nososymbiosity of subgingival microbial communities
and drives periodontitis pathogenicity, remarkably, even at a
low abundance [5]. In this interplay, inflammation is an im-
portant ecological factor that can stimulate outgrowth of
periodontitis-associated microorganisms by tissue destruction
releasing nutrients (e.g., degraded collagen, haeme-containing
complexes, amino acids, and iron). The nutrients are trans-
ferred to the subgingival bacteria, to which P. gingivalis be-
longs, by the inflammatory exudate of the gingival crevicular
fluid. Also increase in genes important for the pathogenesis of
periodontitis such as proteolysis-related genes and genes for
peptide transport and acquisition of iron and genes for synthe-
sis of lipopolysaccharides (LPSs) have been detected. These
genes elevate the proinflammatory potential of the microbial
community [8]. Remodeling of the original biofilm into a
dysbiotic one increases the capability of the biofilm to release
proinflammatory cytokines from host cells [9]. P. gingivalis
also uncouples inflammation from the bactericidal activity of
leukocytes [5]. This subversive action disrupts the microbial
homeostasis and contributes to development of a dysbiotic
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microbiota and periodontitis. Furthermore, P. gingivalis selec-
tively suppresses IL-8 and T helper 1 cell-biasing chemokines
(CXCL9, CXCL10, and CXCL11) [10]. By manipulating
host immunity and keeping bactericidal and inflammatory ac-
tivities apart, P. gingivalis increases the adaptive fitness of the
entire microbial community [4].
Neuroinflammation and Parkinson’s disease
Parkinson’s disease (PD) is characterized by a number of pa-
thologies (Fig. 1) frommisfoldingα-synuclein (αSyn) to neu-
roinflammation, mitochondrial dysfunction, neurotransmitter-
driven changes in neuronal networks of the brain, and affec-
tion of the brain-gut axis (for a review, see Adams et al. [11]).
The present review deals with the possible role ofP. gingivalis
as a driving force in developing PD, focusing on recent
information.
Neuroinflammation is a characteristic feature of PD
[12–14]. There are higher levels of inflammatory cytokines
in the brain of PD patients than in controls, and inflammation
seems to be an important factor in the process of neurodegen-
eration [15]. Furthermore, chronic inflammation, causing dys-
regulation of circulating inflammatory molecules, and an in-
nate immune response seem to be important features in PD
[16]. Both peripheral and brain inflammation contribute to
initiation and progression of the neurodegeneration (for a re-
view, see Adams et al. [11]). Increased levels of circulating
cytokines such as IL-1β, IL-2, IL-10, IL-6, IL-4, TNF-α, C-
reactive protein, RANTES (member of the interleukin-8 su-
perfamily of cytokines), and interferon-gamma (INF-ɣ) have
been found in PD [11, 17, 18], accompanied by oxidative
stress [19]. In addition to significantly increased levels of cir-
culating proinflammatory cytokines, PD was characterized by
hypercoagulability (demonstrated by thromboelastograpy
(TEG), confocal and electron microscopy) and an abnormal
clotting potential [11]. Blood platelets showed marked ultra-
structural changes and amyloid deposition was detected in the
plasma [11].
Porphyromonas gingivalis and Parkinson’s
disease
The reason for the chronic neuroinflammation in PD is un-
clear. Attention has been paid to dormant microbes, which can
shed inflammagens such as LPS and lipoteichoic acid [20,
21]. These are ligands for Toll-like receptor 4 (TLR4) that
can activate inflammation [22]. Bacterial inflammagens that
recently attracted the attention in PD were proteases from the
periodontal pathogen P. gingivalis [11] (Fig. 2). As men-
tioned, this bacterium is considered a keystone pathogen in
periodontitis causing microbial dysbiosis typical of the
pathogenesis. P. gingivalismay also be involved in other sys-
temic inflammatory diseases such as type 2 diabetes mellitus,
Alzheimer’s disease, rheumatoid arthritis, and cardiovascular
disease (for reviews, see [11, 23]).
P. gingivalis has a number of ways to reach the brain from
the infected periodontal pocket [24] and has been detected in
the brain of animals and humans with Alzheimer’s disease
[25, 26] where its LPS and cysteine proteases known as
gingipains have been implicated in disease causation. Asmen-
tioned, proteolysis is important for this bacterium to obtain
nutrition through breakdown of proteins. Gingipains are also
important for degradation of antibacterial peptides [27] and
for the bacterium to evade the complement system [28, 29].
Hypercoagulation, proinflammatory
cytokines, and plasma amyloid formation
in Parkinson’s disease
In the study by Adams et al. [11], PD individuals were found
to have a dysregulated profile of inflammatory biomarkers.
Their whole blood was hypercoagulable with hyperactivated
blood platelets and contained fibrin(ogen) with amyloid fea-
tures. An inter-linked relationship between hypercoagulabili-
ty, presence of inflammatory molecules, and activation of
platelets was suggested. Furthermore, platelet pathology (hy-
peractivation, spreading, aggregation, or clumping), anoma-
lous fibrin(ogen) protein structure, and red blood cell eryptosis
were detected and interpreted as reflecting a systemic inflam-
mation. The significantly upregulated cytokines (IL-1α, IL-
1β, IL-17A, and TNF-α) detected were related to the change
in the ultrastructure of hyperactivated platelets. Fibrinogen
levels have also previously been found to be higher in PD
patients than in healthy controls [30, 31]. In the study by
Adams et al. [11], fibrinogen in clots polymerized into an
increased number of β-sheets that reflected formation of an
amyloid protein structure. These protein changes were visual-
ized using fluorescent amyloid markers called Amytrackers.
Such protein changes might affect the anomalous clot forma-
tion and emphasized the systemic nature of PD. Fibrin(ogen)
that showed an amyloid protein structure (as shown by fluo-
rescent amyloid markers including Amytrackers and
thioflavin T) has also been detected in other diseases with
systemic inflammation such as type 2 diabetes [32, 33] and
Alzheimer’s disease [34] where it is a major feature.
Gingipains and lipopolysaccharide
in Parkinson’s disease
The gingipains Rgp and Kgp of P. gingivalis have been found
to increase the thrombin time compared with controls [35].
Also other coagulation factors can be activated by gingipains
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such as factors IX and X and prothrombin [36, 37]. Therefore,
the homeostatic control of the coagulation system/cascade can
be disrupted when gingipains from P. gingivalis are present.
Adams et al. [11] found, by using polyclonal antibodies, that
gingipain R1 (RgpA) protease produced by P. gingivalis was
present in platelet-poor plasma from PD patients.
Fu r t h e rmo r e , LPS f r om P . g i ng i v a l i s c a u s e d
hypercoagulability and RgpA hydrolyzed fibrin(ogen) so that
healthy coagulation was inhibited.When RgpA and LPS were
co-incubated, hyperclottable fibrin(ogen) could still be seen,
supporting the findings that PD clots are dense and
hyperclottable [38], and that a hyperclottable phenotype exists
in PD patients. Whether the reducing effect of RgpA on clot
formation, in terms of fibrinogen catalyzed by thrombin, also
Fig. 1 (1) Genetic/epigenetic predisposition and (2) environmental fac-
tors that culminate in an individual that will have gut dysbiosis, and/or
gingivitis/periodontitis, vascular dysfunction; (3) an increased presence
of circulating cytokines; resulting in dysregulated hematological system,
e.g., (4) amyloid plasma proteins and increased propensity for
hypercoagulation (an important hallmark of systemic inflammation),
hyperactivated platelets; endothelial dysfunction; (5) ultimately resulting
in Parkinson’s disease also being a true cardiovascular condition, where
circulating inflammatory biomarkers (including bacterial inflammagens)
may be used, not only as early detection of risk but also in tracking
disease status
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occurs in blood plasma in vivo, where protease inhibitors and
other RgpA targets exist, is unknown. However, circulating
bacterial inflammagens such as LPS have also previously
been found in PD [39–42] where they could be involved in
both development and progression of the disease. This implies
that bacteria might participate in PD as drivers of the disease
through endotoxins and exotoxins acting as potent inducers of
cytokines [43].
Intestinal bacteria may also be involved in PD where the
role of the gut-brain-microbiota axis has been emphasized
[44–49]. However, this does not exclude involvement of oral
bacteria since an oral-brain-microbiota axis may exist, as sug-
gested recently for patients with autism spectrum disorder
(ASD) [50]. Interestingly, intestinal dysbiosis has been asso-
ciated with reduced LPS-binding protein in PD [51]. This
protein may reverse the amyloid state of fibrin(ogen) [52].
Sampson et al. [53] reported that in mice, the gut microbiota
was required for motor deficits, microglia activation, and
αSyn pathology. Colonization of αSyn-overexpressing mice
with microbiota from patients with PD increased physical im-
pairments compared with microbiota transplants from healthy
human donors.
Other clinical studies supporting a potential
periodontitis-Parkinson’s disease association
The study by Adams et al. [11] is not the only one reporting an
association between periodontitis and PD. Chen et al. [54]
found in a nationwide population-based case-control study
that patients with periodontitis (n = 176) had a significantly
higher risk of developing PD than controls (n = 275) with
matching sex, age, index of year (occurrence of periodontitis),
and comorbidity (adjusted hazard ratio = 1.431, 95% Cl
[1.141–1.794], p = 0.002). In a similar study, Chen et al.
[55] found that patients without periodontitis who underwent
dental scaling over five consecutive years had a significantly
lower risk of developing PD. Thus, dental scaling, which is
the most common form of prophylaxis and treatment in peri-
odontitis, significantly decreased the risk of developing PD.
Other reports on an association between periodontitis and PD
have come from Schwartz et al. [56], Zlotnik et al. [57], Kaur
et al. [58], Hashioka et al. [59], and Olsen and Singhrao [60].
Although there are several studies indicating that periodontitis
is more common in patients with PD, large longitudinal stud-
ies and randomized case-control or case-cohort studies are
needed to substantiate this association [61].
Concluding remarks
The keystone pathogen of periodontitis, P. gingivalis, has
been used in this paper as an example of a possible bacterial
involvement in PD. The finding of R1 (Rgpa) and LPS, major
inflammagens of P. gingivalis, in the circulation of a PD pop-
ulation, supports a role for P. gingivalis in the development of
PD. This has been supported by several clinical studies.
P. gingivalis cells in brain tissue have not yet been detected,
so the clarification of this question will have to await further
research. Even if the risk of periodontal disease for the devel-
opment of PD and other neurological disorders needs to be
better substantiated, that should not keep us from trying to
Fig. 2 Many individuals with Parkinson’s disease suffer from both (1)
systemic inflammation and (2) periodontitis. One of the bacteria that play
a prominent role in the development of periodontitis is (3) P. gingivalis.
(4) As a result of the systemic inflammation and periodontitis, there is an
increase in circulating inflammatory biomarkers, including cytokines,
iron, and bacterial inflammagens like LPS and proteases like gingipains.
(5) The spread of these biomarkers via the bloodstream leads to a com-
promised blood-brain barrier (BBB) and an entry of particularly the bac-
terial inflammagens from P. gingivalis into the brain, where they may
contribute to and fuel abnormal protein folding resulting in the formation
of the abnormal presence of αSyn and Lewy body development, partic-
ularly in the dopaminergic neurons in the Parkinson’s disease brain
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prevent them by performing periodontitis prophylaxis through
careful daily cleaning of teeth.
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